biostudies-literatureUnknown39 Suppl 1Gerdes S<h4>Background</h4>G-EPOSS is a prospective, non-interventional, German multicentre study of patients with moderate-to-severe plaque psoriasis receiving guselkumab, a therapeutic monoclonal antibody targeting interleukin-23, in a real-world setting.<h4>Objectives</h4>The objective of the study was to evaluate the effectiveness and safety of guselkumab, including its impact on skin, health-related quality of life (HRQoL), sexuality, and perceived stigmatization.<h4>Methods</h4>Patients (≥18 years old) received guselkumab per routine clinical practice. The primary endpoint was the proportion of patients achieving absolute Psoriasis Area and Severity Index (PASI) ≤ 3 at Week (W)28. Secondary endpoint assessments over 28 weeks included the Nail Psoriasis Severity Index (NAPSI), anogenital PhysJournal of the European Academy of Dermatology and Venereology : JEADV15-26https://www.ebi.ac.uk/biostudies/studies/S-EPMC11862875biostudies-literatureEffectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study.PMC11862875Joks GOstendorf RMortazawi DBehrens JTrenkler NMakuc JTabori SGerdes SSuß ATaut FSchadeck TScharfenberger LJacobsen SfalseEffectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study.<h4>Background</h4>G-EPOSS is a prospective, non-interventional, German multicentre study of patients with moderate-to-severe plaque psoriasis receiving guselkumab, a therapeutic monoclonal antibody targeting interleukin-23, in a real-world setting.<h4>Objectives</h4>The objective of the study was to evaluate the effectiveness and safety of guselkumab, including its impact on skin, health-related quality of life (HRQoL), sexuality, and perceived stigmatization.<h4>Methods</h4>Patients (≥18 years old) received guselkumab per routine clinical practice. The primary endpoint was the proportion of patients achieving absolute Psoriasis Area and Severity Index (PASI) ≤ 3 at Week (W)28. Secondary endpoint assessments over 28 weeks included the Nail Psoriasis Severity Index (NAPSI), anogenital Phys2025-01-01T00:00:00Z2025 Mar2025-04-03T23:14:13.04Z2025-04-03T23:14:13.04ZS-EPMC118628753860222510.1111/jdv.19927